论文部分内容阅读
乳腺癌的外科内分泌治疗是从1895年开始,而内分泌药物治疗则始于本世纪30年代末,随着内分泌治疗乳腺癌的作用机制研究的逐步深入,内分泌抬疗药物的研究和应用发展较快,尤自1971年三苯氧胺等药物应用于临床后,内分泌治疗乳腺癌进入了迅速发展的新阶段,激素类药物逐渐取代了外科内分泌治疗;以及逐惭改变了过去认为联合激素治疗乳腺癌疗效差的观点;内分泌治疗联合化疗,可大大地提高患者的生存率,甚至获得治愈。因此内分泌治疗在乳腺癌的综合治疗中已占有重要地位。本文就乳腺癌内分泌治疗的研究进展作一综述。
The surgical endocrine treatment of breast cancer began in 1895, and endocrine drug treatment began in the late 1930s. With the gradual deepening of the research on the mechanism of action of endocrine therapy for breast cancer, the research and application of endocrine booster drugs have developed rapidly. In particular, since tamoxifen and other drugs were used clinically in 1971, endocrine therapy for breast cancer has entered a new stage of rapid development. Hormone drugs have gradually replaced surgical endocrine therapy; and they have changed the past that combined hormone therapy for breast cancer is not effective. Perspective; endocrine therapy combined with chemotherapy can greatly improve the patient’s survival rate, and even get a cure. Therefore, endocrine therapy has played an important role in the comprehensive treatment of breast cancer. This article reviews the research progress of endocrine therapy for breast cancer.